In the news release, The Galien Foundation Honors Michael J. Fox and 2025 Prix Galien Award Recipients, issued Oct. 31, 2025 by The Galien Foundation over PR Newswire, we are advised by a representative of the company that the second row titled “Best Pharmaceutical Product” should read “Gilead Sciences – Yeztugo®” rather than “Gilead Sciences – PHESGO®” as originally issued inadvertently. The complete, corrected release follows:
The Galien Foundation Honors Michael J. Fox and 2025 Prix Galien Award Recipients
TheGalien Foundation, the premier global institution dedicated to honoring innovators in life sciences, celebrated excellence and innovation during the Prix Galien USA Forum and 19th annual Prix Galien Awards Gala last night at the American Museum of Natural History in New York City.
https://mma.prnewswire.com/media/2749810/The_Galien_Foundation__logo.jpg
The evening's highest distinction, The Roy Vagelos Pro Bono Humanum Award for Global Health Equity, was presented to Michael J. Fox in recognition of his extraordinary contributions to Parkinson's disease science. Through founding The Michael J. Fox Foundation, he has propelled groundbreaking research, advanced the development of new therapies, and deepened understanding within the clinician-researcher community. His advocacy has raised global awareness, driven scientific breakthroughs-including the discovery of a biomarker – and offered hope to the more than 6 million patients and families worldwide living with the disease.
“Thank you to The Galien Foundation for the honor of the Roy Vagelos Pro Bono Humanum Award,” said Michael J. Fox. “I share this with the scientists and risk-takers here tonight who will help cure Parkinson's. Elie Wiesel's legacy asks us to repair the world – thank you for honoring our Foundation's work toward that goal.”
Following the presentation of the Roy Vagelos Award, the Prix Galien USA Committees-comprising 25 committee members, 11 subcommittee members, and 15 advisory board members, including three Nobel Laureates-honored the 2025 Prix Galien Award winners in the categories of Best Biotechnology Product, Best Pharmaceutical Product, Best Product for Rare/Orphan Diseases, Best Medical Technology, Best Digital Health Solution, Incubators/Accelerators/Equity, Prix Galien EcoHealth, and Best Startup.
“On behalf of the Prix Galien USA Awards Committee, we extend our highest commendation to all nominees and winners whose groundbreaking work is advancing human health,” said Kenneth Frazier, Prix Galien Committee Chair (categories: Medical Technology, Digital Health, Incubator/Accelerator/Equity, and Startup), former Chairman and Chief Executive Officer, Merck & Co., Inc., Chairman, Health Assurance Initiatives, General Catalyst.
“The Awards Committee takes great pride in recognizing the extraordinary dedication and ingenuity of our nominees,” said Michael Rosenblatt, MD, Chair of the Prix Galien USA Awards Committee, Former Dean of Tufts University School of Medicine, and former Chief Medical Officer of Merck & Co. Inc. “Their steadfast commitment to advancing patient care is exemplary, and we are privileged to celebrate the profound impact of their contributions on global health.”
“It is a privilege to honor another extraordinary group of Prix Galien winners whose innovation, dedication, and vision are advancing the frontiers of the life sciences,” said Bruno Cohen, Chairman of The Galien Foundation. “Our Awards Committee, Prix Galien Alumni, and all members of The Galien Foundation extend our heartfelt congratulations to all nominees and winners and eagerly anticipate the transformative contributions they will continue to bring to medicine and the patient community worldwide.”
The 2025 Prix Galien USA Award Winners
Prix Galien Awards Committee 2025
Biotechnology, Pharmaceutical and Rare/Orphan Diseases:
Michael ROSENBLATTM.D., Galien Forum Co-Chair, Former Dean ofTufts University School of Medicine, and former Chief Medical Officer of Merck & Co. Inc. Prix Galien Committee Chair
Linda BUCKPh.D., Nobel Laureate, Fred Hutchinson Cancer Research Center member; Professor of Physiology and Biophysics,University of Washington
Sue DESMOND-HELLMANNM.D., M.P.H., Former Chief Executive Officer, Bill & Melinda Gates Foundation
Laurie GLIMCHERM.D., President and CEO, Dana Farber Cancer Institute, Professor of Medicine,Harvard Medical School
Mary-Claire KINGPh.D., American Cancer Society Professor of Genome Sciences and Medical Genetics,University of Washington
Robert S. LANGERM.D., David H. Koch Institute Professor,Massachusetts Institute of Technology
Sir Cato T. LAURENCINM.D., Ph.D., K.C.S.L., Chief Executive Officer, The Cato T. Laurencin Institute atUConn; The University Professor and Van Dusen Distinguished Endowed Professor,University of Connecticut
Steven J. LESTERM.D., Medical Director, Discovery Oasis; Founder and Chief Medical Officer,Mayo Clinicand ASU Alliance for Health Care Accelerator
Stanley B. PRUSINERM.D., Nobel Laureate, Professor of Neurology, Director, Institute for Neurodegenerative Diseases,University of California, San Francisco
Phillip A. SHARPPh.D., Nobel Laureate, Professor of Biology and member of the Koch Institute, Chair of the advisory board of the MIT Jameel Clinic
Marc TESSIER-LAVIGNEPh.D., President Emeritus and Professor,Stanford University
Medical Technology, Digital Health, Incubators, Accelerators and Equity, and Startup:
Kenneth C. FRAZIERCommittee Chair, Former Chairman & CEO Merck
Roch DOLIVEUXHonorary CEO, UCB
Dr. Mikael DOLSTENFormer Chief Scientific Officer & President, Pfizer Research and Development
Alex GORSKYFormer CEO & Executive Chairman, Johnson & Johnson
Penny HEATONGlobal Therapeutic Area Head, Vaccines, Janssen
Sheri McCOYBoard of Directors, AstraZeneca, Former CEO,Avon
Joel S. MARCUSExecutive Chairman & Founder,Alexandria
Elias ZERHOUNIFormer Head of Global R&D, Sanofi
Prix Galien USA EcoHealth
Adam SCHECHTERCommittee ChairChairman and CEO, Labcorp
Gil BASHEChair Global Health and Purpose, FINN PartnersEditor-in-Chief,Medika LifeGalien Foundation Committee Liaison
Ouided BOUCHAMAOUINobel Peace PrizeProfessor of Practice of Diplomacy and Conflict Resolution at NYU Abu Dhabi
Pr. Awa Marie COLL-SECK, MD, PhDFormer Senior Minister to the President of SenegalFormer Minister of HealthChair of Galien Africa
Judith DIMENT MBEDean Rotary Representatives to the United Nations 2020-2024Vice Chair International Polio Plus CommitteeRotary Representative, Commonwealth Nations
James E.K. HILDRETH, Ph.D., MDPresident and CEO, Meharry Medical College
Prix Galien Medical Technology Sub-Committee:
Robert S. LANGERDavid H. Koch Institute Professor, Massachusetts Institute of Technology
Cato T. LAURENCINM.D., Ph.D., University Professor, University of Connecticut
Steven LESTERM.D., Chief Medical Officer, Mayo Clinic-ASU MedTech Accelerator
Bernard POUSSOTDirector, Roche Holding, Former Chairman & CEO, Wyeth, Chairman Prix Galien, In Memoriam
Prix Galien Incubators, Accelerators, and Equity Category Sub Committee:
Gil BASHEManaging Partner, Chair Global Health and Purpose, FINN Partners
Ron COHENM.D., Founder, President & CEO, Acorda Therapeutics
Jamey EDWARDSFormer CEO, Emergent Medical Associates
Amir KALALIM.D., Chairman & Chief Curator CNS Summit/Co-Chair Decentralized Trial Research Alliance
Michelle LONGMIREM.D., Co-Founder & CEO, Medable Inc.
James PRUTOWJ.D., MBA, Advisory Partner – Life Sciences, Molecular Diagnostics, Global Healthcare, PwC Consulting
Julien de SALABERRY
CEO & Founder, Galen Growth
Prix Galien Startup Advisory Board:
Elaine BRENNANExecutive Director, Global Strategic Partnerships, Northwell Health
Rodolphe KATRAPh.D.,Sr. Research Director & Technical Fellow, Medtronic
Michael LANGERFounder and Managing Partner at T.Rx Capital
Jonathan MARCHADOManaging Director, Samsung Nex
Detlev MENNERICHCorporate SVP, Global Head of Business Development &Licensing (BD&L), Boehringer Ingelheim
Leighanne OHMS, Life Sciences Investor, Novo Holding
Denis PATRICPh.D., Emerging Science & Innovation, Partnering Pfizer
Dennis PURCELLFounder, Aisling Capital
Prix Galien Digital Health Advisory Board:
Junaid BAJWAChief Medical Scientist, Microsoft Research, Microsoft
Ariel KATZCEO and Co-founder, H1
Sachin NANAVATIHead, Industry, Healthcare, Google
Jay RAJDAM.D., Clinical Leader, Healthcare, Amazon
MaryAnne RIZKPh.D., Managing Partner, Rizk Management Advisors, Adjunct Professor, Stevens Institute of Technology
Steven ROSENBERGChief Executive Officer, uMotif
Daniel VIALFormer Advisor of Sanofi CEO, Healthcare Consultant
About The Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.
The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
For more information, visit https://www.galienfoundation.org/.
Media Contact:Kara BradleyFinn PartnersKara.Bradley@finnpartners.com646-213-7243
https://edge.prnewswire.com/c/img/favicon.png?sn=NY12122A&sd=2025-10-31
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-galien-foundation-honors-michael-j-fox-and-2025-prix-galien-award-recipients-302600699.html
SOURCE The Galien Foundation
https://rt.newswire.ca/rt.gif?NewsItemId=NY12122&Transmission_Id=202510311150PR_NEWS_USPR_____NY12122A&DateId=20251031